{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:06Z","timestamp":1792788726843,"version":"4.5.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Ministerstwo Nauki i Szkolnictwa Wy\u017cszego","doi-asserted-by":"crossref","award":["Maria Sklodowska-Curie National Research Institute of Oncolog Statutory Founding"],"award-info":[{"award-number":["Maria Sklodowska-Curie National Research Institute of Oncolog Statutory Founding"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The introduction of novel targeted therapies during the last 2 decades has led to a significant improvement in patients' clinical outcomes with renal cell carcinoma. However, this improvement came at the price of a whole new spectrum of adverse events, including renal toxicity. Systemic treatment of patients with kidney neoplasms who often present with impairment of kidney function, even prior to treatment, poses an increasing diagnostic and therapeutic challenge for clinicians. Common lifestyle-related comorbidities, i.e., hypertension and diabetes, may contribute to further impairment of kidney function. The lack of official guidelines and the exclusion of patients with reduced kidney function from the clinical trials of recently approved drugs complicate the issue even further. Early detection and correct management of renal toxic effects are crucial to preserve kidney function and ensure the optimal administration of life-prolonging therapies. This review presents detailed information on the renal toxicities of three groups of drugs commonly used in renal cell carcinoma treatment: tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and immune checkpoint inhibitors. We outline the incidence and underlying mechanisms of renal adverse effects with a focus on patients on renal replacement therapy, as well as present suggestions for their management.<\/jats:p>","DOI":"10.1007\/s00280-021-04260-y","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T23:30:09Z","timestamp":1616715009000},"page":"723-742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function"],"prefix":"10.1007","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4840-2442","authenticated-orcid":false,"given":"\u0141ukasz","family":"Mielczarek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0017-1040","authenticated-orcid":false,"given":"Anna","family":"Brodziak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4103-1626","authenticated-orcid":false,"given":"Pawe\u0142","family":"Sobczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7858-6214","authenticated-orcid":false,"given":"Maciej","family":"Kawecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-291X","authenticated-orcid":false,"given":"Agnieszka","family":"Cudnoch-J\u0119drzejewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-3810","authenticated-orcid":false,"given":"Anna M.","family":"Czarnecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"issue":"1","key":"4260_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD (2020) Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4260_CR2","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.juro.2013.04.130","volume":"190","author":"LC Macleod","year":"2013","unstructured":"Macleod LC, Hotaling JM, Wright JL, Davenport MT, Gore JL, Harper J, White E (2013) Risk factors for renal cell carcinoma in the VITAL study. J Urol 190(5):1657\u20131661. https:\/\/doi.org\/10.1016\/j.juro.2013.04.130","journal-title":"J Urol"},{"issue":"1","key":"4260_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","volume":"75","author":"U Capitanio","year":"2019","unstructured":"Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C, Russo P (2019) Epidemiology of renal cell carcinoma. Eur Urol 75(1):74\u201384. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.036","journal-title":"Eur Urol"},{"issue":"7","key":"4260_CR4","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.2337\/dc11-0132","volume":"34","author":"HK Joh","year":"2011","unstructured":"Joh HK, Willett WC, Cho E (2011) Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care 34(7):1552\u20131556. https:\/\/doi.org\/10.2337\/dc11-0132","journal-title":"Diabetes Care"},{"issue":"9","key":"4260_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(06)70803-8","volume":"7","author":"WC Huang","year":"2006","unstructured":"Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, Scardino PT, Russo P (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7(9):735\u2013740. https:\/\/doi.org\/10.1016\/S1470-2045(06)70803-8","journal-title":"Lancet Oncol"},{"issue":"1","key":"4260_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/nep.13209","volume":"24","author":"P Kompotiatis","year":"2019","unstructured":"Kompotiatis P, Thongprayoon C, Manohar S, Cheungpasitporn W, Gonzalez Suarez ML, Craici IM, Mao MA, Herrmann SM (2019) Association between urologic malignancies and end-stage renal disease: a meta-analysis. Nephrology (Carlton) 24(1):65\u201373. https:\/\/doi.org\/10.1111\/nep.13209","journal-title":"Nephrology (Carlton)"},{"issue":"4","key":"4260_CR7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/jcm8040530","volume":"8","author":"A Chewcharat","year":"2019","unstructured":"Chewcharat A, Thongprayoon C, Bathini T, Aeddula NR, Boonpheng B, Kaewput W, Watthanasuntorn K, Lertjitbanjong P, Sharma K, Torres-Ortiz A, Leeaphorn N, Mao MA, Khoury NJ, Cheungpasitporn W (2019) Incidence and mortality of renal cell carcinoma after kidney transplantation: a meta-analysis. J Clin Med 8(4):530. https:\/\/doi.org\/10.3390\/jcm8040530","journal-title":"J Clin Med"},{"issue":"3","key":"4260_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.eururo.2016.10.008","volume":"71","author":"GW Dy","year":"2017","unstructured":"Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C (2017) Global burden of urologic cancers, 1990\u20132013. Eur Urol 71(3):437\u2013446. https:\/\/doi.org\/10.1016\/j.eururo.2016.10.008","journal-title":"Eur Urol"},{"issue":"2","key":"4260_CR9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.eururo.2011.02.035","volume":"60","author":"Y Neuzillet","year":"2011","unstructured":"Neuzillet Y, Tillou X, Mathieu R, Long JA, Gigante M, Paparel P, Poissonnier L, Baumert H, Escudier B, Lang H, Rioux-Leclercq N, Bigot P, Bernhard JC, Albiges L, Bastien L, Petit J, Saint F, Bruyere F, Boutin JM, Brichart N, Karam G, Branchereau J, Ferriere JM, Wallerand H, Barbet S, Elkentaoui H, Hubert J, Feuillu B, Theveniaud PE, Villers A, Zini L, Descazeaux A, Roupret M, Barrou B, Fehri K, Lebret T, Tostain J, Terrier JE, Terrier N, Martin L, Dugardin F, Galliot I, Staerman F, Azemar MD, Irani J, Tisserand B, Timsit MO, Sallusto F, Rischmann P, Guy L, Valeri A, Deruelle C, Azzouzi AR, Chautard D, Mejean A, Salomon L, Rigaud J, Pfister C, Soulie M, Kleinclauss F, Badet L, Patard JJ, Comite de Transplantation de l\u2019Association Francaise dU, Comite de Cancerologie de l\u2019Association Francaise dU (2011) Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol 60(2):366\u2013373. https:\/\/doi.org\/10.1016\/j.eururo.2011.02.035","journal-title":"Eur Urol"},{"issue":"3","key":"4260_CR10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/21681805.2015.1019561","volume":"49","author":"K Chen","year":"2015","unstructured":"Chen K, Huang HH, Aydin H, Tan YH, Lau WK, Cheng CW, Yuen JS (2015) Renal cell carcinoma in patients with end-stage renal disease is associated with more favourable histological features and prognosis. Scand J Urol 49(3):200\u2013204. https:\/\/doi.org\/10.3109\/21681805.2015.1019561","journal-title":"Scand J Urol"},{"issue":"9","key":"4260_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/iju.13759","volume":"25","author":"T Tsuzuki","year":"2018","unstructured":"Tsuzuki T, Iwata H, Murase Y, Takahara T, Ohashi A (2018) Renal tumors in end-stage renal disease: a comprehensive review. Int J Urol 25(9):780\u2013786. https:\/\/doi.org\/10.1111\/iju.13759","journal-title":"Int J Urol"},{"key":"4260_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/1471-2369-15-181","volume":"15","author":"CS Kim","year":"2014","unstructured":"Kim CS, Bae EH, Ma SK, Kweon SS, Kim SW (2014) Impact of partial nephrectomy on kidney function in patients with renal cell carcinoma. BMC Nephrol 15:181. https:\/\/doi.org\/10.1186\/1471-2369-15-181","journal-title":"BMC Nephrol"},{"key":"4260_CR13","doi-asserted-by":"publisher","unstructured":"Schmid M, Krishna N, Ravi P, Meyer CP, Becker A, Dalela D, Sood A, Chun FK, Kibel AS, Menon M, Fisch M, Trinh QD, Sun M (2016) Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. Urol Oncol 34 (7):293 e291\u2013293\u2013e210. https:\/\/doi.org\/10.1016\/j.urolonc.2016.02.018","DOI":"10.1016\/j.urolonc.2016.02.018"},{"issue":"6","key":"4260_CR14","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/BF02303649","volume":"5","author":"G Grimaldi","year":"1998","unstructured":"Grimaldi G, Reuter V, Russo P (1998) Bilateral non-familial renal cell carcinoma. Ann Surg Oncol 5(6):548\u2013552. https:\/\/doi.org\/10.1007\/BF02303649","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"4260_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/s0094-0143(03)00056-9","volume":"30","author":"NK Janzen","year":"2003","unstructured":"Janzen NK, Kim HL, Figlin RA, Belldegrun AS (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin N Am 30(4):843\u2013852. https:\/\/doi.org\/10.1016\/s0094-0143(03)00056-9","journal-title":"Urol Clin N Am"},{"issue":"9","key":"4260_CR16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/ndt\/gfy188","volume":"33","author":"L Cosmai","year":"2018","unstructured":"Cosmai L, Porta C, Perazella MA, Launay-Vacher V, Rosner MH, Jhaveri KD, Floris M, Pani A, Teuma C, Szczylik CA, Gallieni M (2018) Opening an onconephrology clinic: recommendations and basic requirements. Nephrol Dial Transplant 33(9):1503\u20131510. https:\/\/doi.org\/10.1093\/ndt\/gfy188","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"4260_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115\u2013124. https:\/\/doi.org\/10.1056\/NEJMoa065044","journal-title":"N Engl J Med"},{"issue":"22","key":"4260_CR18","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584\u20133590. https:\/\/doi.org\/10.1200\/JCO.2008.20.1293","journal-title":"J Clin Oncol"},{"issue":"1","key":"4260_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/02841860802314720","volume":"48","author":"X Zhu","year":"2009","unstructured":"Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48(1):9\u201317. https:\/\/doi.org\/10.1080\/02841860802314720","journal-title":"Acta Oncol"},{"issue":"1","key":"4260_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/fon-2016-0355","volume":"13","author":"AM Czarnecka","year":"2017","unstructured":"Czarnecka AM, Sobczuk P, Korniluk J, Spychalska M, Bogusz K, Owczarek A, Brodziak A, Labochka D, Moszczuk B, Szczylik C (2017) Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma. Future Oncol 13(1):31\u201349. https:\/\/doi.org\/10.2217\/fon-2016-0355","journal-title":"Future Oncol"},{"issue":"1","key":"4260_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3904\/kjim.2014.29.1.40","volume":"29","author":"SH Baek","year":"2014","unstructured":"Baek SH, Kim H, Lee J, Kim DK, Oh KH, Kim YS, Han JS, Kim TM, Lee SH, Joo KW (2014) Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. Korean J Intern Med 29(1):40\u201348. https:\/\/doi.org\/10.3904\/kjim.2014.29.1.40","journal-title":"Korean J Intern Med"},{"issue":"8","key":"4260_CR22","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/CAD.0b013e328346af0d","volume":"22","author":"S Gupta","year":"2011","unstructured":"Gupta S, Parsa V, Heilbrun LK, Smith DW, Dickow B, Heath E, Vaishampayan U (2011) Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. Anticancer Drugs 22(8):794\u2013800. https:\/\/doi.org\/10.1097\/CAD.0b013e328346af0d","journal-title":"Anticancer Drugs"},{"issue":"9807","key":"4260_CR23","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(11)61613-9","journal-title":"Lancet"},{"issue":"8","key":"4260_CR24","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722\u2013731. https:\/\/doi.org\/10.1056\/NEJMoa1303989","journal-title":"N Engl J Med"},{"issue":"3","key":"4260_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11523-015-0395-4","volume":"11","author":"H Miyake","year":"2016","unstructured":"Miyake H, Muramaki M, Imai S, Harada K, Fujisawa M (2016) Changes in renal function of patients with metastatic renal cell carcinoma during treatment with molecular-targeted agents. Target Oncol 11(3):329\u2013335. https:\/\/doi.org\/10.1007\/s11523-015-0395-4","journal-title":"Target Oncol"},{"issue":"3","key":"4260_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/17512433.2020.1734450","volume":"13","author":"W Zhang","year":"2020","unstructured":"Zhang W, Feng LJ, Teng F, Li YH, Zhang X, Ran YG (2020) Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol 13(3):311\u2013320. https:\/\/doi.org\/10.1080\/17512433.2020.1734450","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"4260_CR27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","volume":"46","author":"H Izzedine","year":"2010","unstructured":"Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC (2010) VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 46(2):439\u2013448. https:\/\/doi.org\/10.1016\/j.ejca.2009.11.001","journal-title":"Eur J Cancer"},{"issue":"9","key":"4260_CR28","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.humpath.2014.05.015","volume":"45","author":"J Usui","year":"2014","unstructured":"Usui J, Glezerman IG, Salvatore SP, Chandran CB, Flombaum CD, Seshan SV (2014) Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum Pathol 45(9):1918\u20131927. https:\/\/doi.org\/10.1016\/j.humpath.2014.05.015","journal-title":"Hum Pathol"},{"issue":"5","key":"4260_CR29","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/ndt\/gfr093","volume":"26","author":"K Stylianou","year":"2011","unstructured":"Stylianou K, Lioudaki E, Papadimitraki E, Kokologiannakis G, Kroustalakis N, Liotsi C, Giannakakis K, Georgoulias V, Daphnis E (2011) Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. Nephrol Dial Transplant 26(5):1742\u20131745. https:\/\/doi.org\/10.1093\/ndt\/gfr093","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"4260_CR30","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/ndt\/gfp140","volume":"24","author":"EJ Rolleman","year":"2009","unstructured":"Rolleman EJ, Weening J, Betjes MGH (2009) Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma. Nephrol Dial Transplant 24(6):2002\u20132003. https:\/\/doi.org\/10.1093\/ndt\/gfp140","journal-title":"Nephrol Dial Transplant"},{"key":"4260_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/ott.s4052","volume":"2","author":"A Schwandt","year":"2009","unstructured":"Schwandt A, Wood LS, Rini B, Dreicer R (2009) Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther 2:51\u201361. https:\/\/doi.org\/10.2147\/ott.s4052","journal-title":"Onco Targets Ther"},{"issue":"4","key":"4260_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","volume":"56","author":"MH Kappers","year":"2010","unstructured":"Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH (2010) Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56(4):675\u2013681. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.149690","journal-title":"Hypertension"},{"issue":"6","key":"4260_CR33","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","volume":"65","author":"BF Schrijvers","year":"2004","unstructured":"Schrijvers BF, Flyvbjerg A, De Vriese AS (2004) The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65(6):2003\u20132017. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00621.x","journal-title":"Kidney Int"},{"issue":"3","key":"4260_CR34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/S0002-9440(10)61782-8","volume":"159","author":"M Simons","year":"2001","unstructured":"Simons M, Schwarz K, Kriz W, Miettinen A, Reiser J, Mundel P, Holthofer H (2001) Involvement of lipid rafts in nephrin phosphorylation and organization of the glomerular slit diaphragm. Am J Pathol 159(3):1069\u20131077. https:\/\/doi.org\/10.1016\/S0002-9440(10)61782-8","journal-title":"Am J Pathol"},{"issue":"1","key":"4260_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12894-019-0481-5","volume":"19","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhou L, Chen Y, Liao B, Ye D, Wang K, Li H (2019) Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. BMC Urol 19(1):49. https:\/\/doi.org\/10.1186\/s12894-019-0481-5","journal-title":"BMC Urol"},{"issue":"12","key":"4260_CR36","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/bjc.2016.147","volume":"114","author":"MJ Sorich","year":"2016","unstructured":"Sorich MJ, Rowland A, Kichenadasse G, Woodman RJ, Mangoni AA (2016) Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. Br J Cancer 114(12):1313\u20131317. https:\/\/doi.org\/10.1038\/bjc.2016.147","journal-title":"Br J Cancer"},{"issue":"4","key":"4260_CR37","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ctrv.2012.12.006","volume":"39","author":"A Alasker","year":"2013","unstructured":"Alasker A, Meskawi M, Sun M, Ismail S, Hanna N, Hansen J, Tian Z, Bianchi M, Perrotte P, Karakiewicz PI (2013) A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. Cancer Treat Rev 39(4):388\u2013401. https:\/\/doi.org\/10.1016\/j.ctrv.2012.12.006","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"4260_CR38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nrneph.2015.15","volume":"11","author":"C Porta","year":"2015","unstructured":"Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F (2015) Renal effects of targeted anticancer therapies. Nat Rev Nephrol 11(6):354\u2013370. https:\/\/doi.org\/10.1038\/nrneph.2015.15","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"4260_CR39","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358(11):1129\u20131136. https:\/\/doi.org\/10.1056\/NEJMoa0707330","journal-title":"N Engl J Med"},{"issue":"2","key":"4260_CR40","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/ndt\/gfn657","volume":"24","author":"G Bollee","year":"2009","unstructured":"Bollee G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, Bruneval P, Noel LH, Knebelmann B (2009) Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transpl 24(2):682\u2013685. https:\/\/doi.org\/10.1093\/ndt\/gfn657","journal-title":"Nephrol Dial Transpl"},{"issue":"24","key":"4260_CR41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MD.0000000000000207","volume":"93","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, Baumelou A, Derosa L, Bahleda R, Hollebecque A, Sahali D, Soria JC (2014) Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore) 93(24):333\u2013339. https:\/\/doi.org\/10.1097\/MD.0000000000000207","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"4260_CR42","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.urolonc.2009.07.023","volume":"29","author":"V Launay-Vacher","year":"2011","unstructured":"Launay-Vacher V, Ayllon J, Janus N, Medioni J, Deray G, Isnard-Bagnis C, Oudard S (2011) Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. Urol Oncol 29(5):492\u2013494. https:\/\/doi.org\/10.1016\/j.urolonc.2009.07.023","journal-title":"Urol Oncol"},{"issue":"8","key":"4260_CR43","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1093\/annonc\/mdp603","volume":"21","author":"G Khan","year":"2010","unstructured":"Khan G, Golshayan A, Elson P, Wood L, Garcia J, Bukowski R, Rini B (2010) Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 21(8):1618\u20131622. https:\/\/doi.org\/10.1093\/annonc\/mdp603","journal-title":"Ann Oncol"},{"issue":"4","key":"4260_CR44","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/0091270009347868","volume":"50","author":"R Khosravan","year":"2010","unstructured":"Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, Swan SK, Lunde NM, Bello CL (2010) Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 50(4):472\u2013481. https:\/\/doi.org\/10.1177\/0091270009347868","journal-title":"J Clin Pharmacol"},{"issue":"9 Supplement","key":"4260_CR45","first-page":"934","volume":"67","author":"W Smith","year":"2007","unstructured":"Smith W, Marbury T, Kipnes M, Cihon F, Lettieri J, Mazzu A (2007) Effects of renal impairment on the pharmacokinetics of sorafenib and its metabolites. Cancer Res 67(9 Supplement):934","journal-title":"Cancer Res"},{"issue":"2","key":"4260_CR46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11523-015-0389-2","volume":"11","author":"Y Chen","year":"2016","unstructured":"Chen Y, Rini BI, Motzer RJ, Dutcher JP, Rixe O, Wilding G, Stadler WM, Tarazi J, Garrett M, Pithavala YK (2016) Effect of renal impairment on the pharmacokinetics and safety of axitinib. Target Oncol 11(2):229\u2013234. https:\/\/doi.org\/10.1007\/s11523-015-0389-2","journal-title":"Target Oncol"},{"issue":"2","key":"4260_CR47","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cncr.26201","volume":"118","author":"R Macfarlane","year":"2012","unstructured":"Macfarlane R, Heng DYC, Xie W, Knox JJ, McDermott DF, Rini BI, Kollmannsberger C, Choueiri TK (2012) The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. Cancer 118(2):365\u2013370. https:\/\/doi.org\/10.1002\/cncr.26201","journal-title":"Cancer"},{"issue":"1","key":"4260_CR48","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1016\/j.clgc.2018.10.001","volume":"17","author":"C Masini","year":"2019","unstructured":"Masini C, Vitale MG, Maruzzo M, Procopio G, de Giorgi U, Buti S, Rossetti S, Iacovelli R, Atzori F, Cosmai L, Vignani F, Prati G, Scagliarini S, Guida A, Berselli A, Pinto C (2019) Safety and efficacy of pazopanib in first-line metastatic renal-cell carcinoma with or without renal failure: CORE-URO-01 study. Clin Genitourin Cancer 17(1):e150\u2013e155. https:\/\/doi.org\/10.1016\/j.clgc.2018.10.001","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"4260_CR49","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/jjco\/hyr015","volume":"41","author":"T Kennoki","year":"2011","unstructured":"Kennoki T, Kondo T, Kimata N, Murakami J, Ishimori I, Nakazawa H, Hashimoto Y, Kobayashi H, Iizuka J, Takagi T, Yoshida K, Tanabe K (2011) Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn J Clin Oncol 41(5):647\u2013655. https:\/\/doi.org\/10.1093\/jjco\/hyr015","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"4260_CR50","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/annonc\/mdn626","volume":"20","author":"H Izzedine","year":"2009","unstructured":"Izzedine H, Etienne-Grimaldi MC, Ren\u00e9e N, Vignot S, Milano G (2009) Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol 20(1):190\u2013192. https:\/\/doi.org\/10.1093\/annonc\/mdn626","journal-title":"Ann Oncol"},{"issue":"6","key":"4260_CR51","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00280-017-3320-y","volume":"79","author":"A Thiery-Vuillemin","year":"2017","unstructured":"Thiery-Vuillemin A, Orillard E, Mouillet G, Calcagno F, Devillard N, Bouchet S, Royer B (2017) Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma. Cancer Chemother Pharmacol 79(6):1273\u20131276. https:\/\/doi.org\/10.1007\/s00280-017-3320-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4260_CR52","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1016\/j.clgc.2016.03.016","volume":"14","author":"S Noda","year":"2016","unstructured":"Noda S, Hira D, Kageyama S, Jo F, Wada A, Yoshida T, Kawauchi A, Morita S-y, Terada T (2016) Pharmacokinetic analysis of a hemodialyzed patient treated with pazopanib. Clin Genitourin Cancer 14(4):e453\u2013e456. https:\/\/doi.org\/10.1016\/j.clgc.2016.03.016","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"4260_CR53","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.clgc.2016.01.010","volume":"14","author":"A Leonetti","year":"2016","unstructured":"Leonetti A, Bersanelli M, Castagneto B, Masini C, Di Meglio G, Pellegrino B, Buti S (2016) Outcome and safety of sorafenib in metastatic renal cell carcinoma dialysis patients: a systematic review. Clin Genitourin Cancer 14(4):277\u2013283. https:\/\/doi.org\/10.1016\/j.clgc.2016.01.010","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"4260_CR54","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/s1470-2045(09)70162-7","volume":"10","author":"ME Gore","year":"2009","unstructured":"Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Sch\u00f6ffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757\u2013763. https:\/\/doi.org\/10.1016\/s1470-2045(09)70162-7","journal-title":"Lancet Oncol"},{"issue":"5","key":"4260_CR55","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/cncr.24864","volume":"116","author":"WM Stadler","year":"2010","unstructured":"Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116(5):1272\u20131280. https:\/\/doi.org\/10.1002\/cncr.24864","journal-title":"Cancer"},{"issue":"15","key":"4260_CR56","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2174\/1389450117666160112114756","volume":"17","author":"M Bersanelli","year":"2016","unstructured":"Bersanelli M, Facchinetti F, Tiseo M, Maiorana M, Buti S (2016) Pazopanib in renal cell carcinoma dialysis patients: a mini-review and a case report. Curr Drug Targets 17(15):1755\u20131760. https:\/\/doi.org\/10.2174\/1389450117666160112114756","journal-title":"Curr Drug Targets"},{"issue":"11","key":"4260_CR57","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/iju.14093","volume":"26","author":"H Ishihara","year":"2019","unstructured":"Ishihara H, Takagi T, Kondo T, Yoshida K, Okumi M, Tanabe K (2019) Efficacy and safety of axitinib for metastatic renal cell carcinoma in patients on hemodialysis for end-stage renal disease: case series of eight patients. Int J Urol 26(11):1081\u20131082. https:\/\/doi.org\/10.1111\/iju.14093","journal-title":"Int J Urol"},{"issue":"12","key":"4260_CR58","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.urolonc.2015.07.020","volume":"33","author":"A Pham","year":"2015","unstructured":"Pham A, Ye D-W, Pal S (2015) Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma. Urol Oncol Semin Orig Investig 33(12):517\u2013527. https:\/\/doi.org\/10.1016\/j.urolonc.2015.07.020","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"2","key":"4260_CR59","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4081\/oncol.2019.455","volume":"13","author":"RK Paluri","year":"2019","unstructured":"Paluri RK, Sonpavde G, Morgan C, Rojymon J, Mar AH, Gangaraju R (2019) Renal toxicity with mammalian target of rapamycin inhibitors: a meta-analysis of randomized clinical trials. Oncol Rev 13(2):455\u2013455. https:\/\/doi.org\/10.4081\/oncol.2019.455","journal-title":"Oncol Rev"},{"issue":"8","key":"4260_CR60","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1093\/annonc\/mdt155","volume":"24","author":"TK Choueiri","year":"2013","unstructured":"Choueiri TK, Je Y, Sonpavde G, Richards CJ, Galsky MD, Nguyen PL, Schutz F, Heng DY, Kaymakcalan MD (2013) Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Ann Oncol 24(8):2092\u20132097. https:\/\/doi.org\/10.1093\/annonc\/mdt155","journal-title":"Ann Oncol"},{"issue":"4","key":"4260_CR61","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.transproceed.2009.03.093","volume":"41","author":"E Bertoni","year":"2009","unstructured":"Bertoni E, Bruschi M, Candiano G, Boccardi C, Citti L, Mangraviti S, Rosso G, Larti A, Rosati A, Ghiggeri GM, Salvadori M (2009) Posttransplant proteinuria associated with everolimus. Transpl Proc 41(4):1216\u20131217. https:\/\/doi.org\/10.1016\/j.transproceed.2009.03.093","journal-title":"Transpl Proc"},{"issue":"4","key":"4260_CR62","doi-asserted-by":"publisher","first-page":"F693","DOI":"10.1152\/ajprenal.2001.281.4.F693","volume":"281","author":"W Lieberthal","year":"2001","unstructured":"Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, Koh JS, Valeri R, Levine JS (2001) Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281(4):F693-706. https:\/\/doi.org\/10.1152\/ajprenal.2001.281.4.F693","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"4260_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/01.tp.0000225772.22757.5e","volume":"82","author":"W Lieberthal","year":"2006","unstructured":"Lieberthal W, Fuhro R, Andry C, Patel V, Levine JS (2006) Rapamycin delays but does not prevent recovery from acute renal failure: role of acquired tubular resistance. Transplantation 82(1):17\u201322. https:\/\/doi.org\/10.1097\/01.tp.0000225772.22757.5e","journal-title":"Transplantation"},{"issue":"1","key":"4260_CR64","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ejphar.2012.09.010","volume":"696","author":"S Nakagawa","year":"2012","unstructured":"Nakagawa S, Nishihara K, Inui K-i, Masuda S (2012) Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. Eur J Pharmacol 696(1):143\u2013154. https:\/\/doi.org\/10.1016\/j.ejphar.2012.09.010","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"4260_CR65","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/annonc\/mdt233","volume":"24","author":"H Izzedine","year":"2013","unstructured":"Izzedine H, Escudier B, Rouvier P, Gueutin V, Varga A, Bahleda R, Soria JC (2013) Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven. Ann Oncol 24(9):2421\u20132425. https:\/\/doi.org\/10.1093\/annonc\/mdt233","journal-title":"Ann Oncol"},{"issue":"11","key":"4260_CR66","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1097\/01.tp.0000282866.92367.99","volume":"84","author":"R Vogelbacher","year":"2007","unstructured":"Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C (2007) The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 84(11):1492\u20131499. https:\/\/doi.org\/10.1097\/01.tp.0000282866.92367.99","journal-title":"Transplantation"},{"issue":"2","key":"4260_CR67","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov DD, Ali SM, Sengupta S, Sheen J-H, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol Cell 22(2):159\u2013168. https:\/\/doi.org\/10.1016\/j.molcel.2006.03.029","journal-title":"Mol Cell"},{"issue":"2","key":"4260_CR68","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.trre.2007.12.001","volume":"22","author":"E Letavernier","year":"2008","unstructured":"Letavernier E, Legendre C (2008) mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev 22(2):125\u2013130. https:\/\/doi.org\/10.1016\/j.trre.2007.12.001","journal-title":"Transplant Rev"},{"key":"4260_CR69","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1186\/1471-2407-14-906","volume":"14","author":"SH Ha","year":"2014","unstructured":"Ha SH, Park JH, Jang HR, Huh W, Lim H-Y, Kim Y-G, Kim DJ, Oh HY, Lee JE (2014) Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function. BMC Cancer 14:906\u2013906. https:\/\/doi.org\/10.1186\/1471-2407-14-906","journal-title":"BMC Cancer"},{"issue":"4","key":"4260_CR70","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.4143\/crt.2016.018","volume":"48","author":"KH Kim","year":"2016","unstructured":"Kim KH, Kim JH, Lee JY, Kim HS, Heo SJ, Kim JH, Kim HY, Rha SY (2016) Efficacy and toxicity of mammalian target rapamycin inhibitors in patients with metastatic renal cell carcinoma with renal insufficiency: the Korean Cancer Study Group GU 14\u201308. Cancer Res Treat 48(4):1286\u20131292. https:\/\/doi.org\/10.4143\/crt.2016.018","journal-title":"Cancer Res Treat"},{"key":"4260_CR71","doi-asserted-by":"publisher","unstructured":"Lunardi G, Vannozzi MO, Armirotti A, Nicodemo M, Venturini M, Cavallini L (2008) Temsirolimus in patients with renal cancer on hemodialysis. J Clin Oncol 26 (34):5652\u20135653; author reply 5653\u20135654. https:\/\/doi.org\/10.1200\/JCO.2008.19.3144","DOI":"10.1200\/JCO.2008.19.3144"},{"issue":"11","key":"4260_CR72","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1093\/annonc\/mds477","volume":"23","author":"A Thiery-Vuillemin","year":"2012","unstructured":"Thiery-Vuillemin A, Curtit E, Maurina T, Montange D, Succi C, Nguyen T, Kim S, Montcuquet P, Pivot X, Royer B (2012) Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer. Ann Oncol 23(11):2992\u20132993. https:\/\/doi.org\/10.1093\/annonc\/mds477","journal-title":"Ann Oncol"},{"issue":"23","key":"4260_CR73","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.2217\/fon.15.256","volume":"11","author":"A Guida","year":"2015","unstructured":"Guida A, Masini C, Milella M, Di Lorenzo G, Santoni M, Prati V, Porta C, Cosmai L, Donati D, del Giovane C, Mighali P, Sabbatini R (2015) Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. Future Oncol 11(23):3159\u20133166. https:\/\/doi.org\/10.2217\/fon.15.256","journal-title":"Future Oncol"},{"issue":"18","key":"4260_CR74","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gr\u00fcnwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, for the R-SG (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer 116(18):4256\u20134265. https:\/\/doi.org\/10.1002\/cncr.25219","journal-title":"Cancer"},{"issue":"5","key":"4260_CR75","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Gr\u00fcnwald V, Gillessen S, Horwich A (2019) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 30(5):706\u2013720. https:\/\/doi.org\/10.1093\/annonc\/mdz056","journal-title":"Ann Oncol"},{"issue":"2","key":"4260_CR76","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"DLMD Longo","year":"2018","unstructured":"Longo DLMD, Postow MAMD, Sidlow RMD, Hellmann MDMD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"issue":"12","key":"4260_CR77","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","volume":"14","author":"H Seethapathy","year":"2019","unstructured":"Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, Cortazar FB, Leaf DE, Mooradian MJ, Villani A-C, Sullivan RJ, Reynolds K, Sise ME (2019) The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14(12):1692. https:\/\/doi.org\/10.2215\/CJN.00990119","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4260_CR78","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ndt\/gfy105","volume":"34","author":"S Manohar","year":"2018","unstructured":"Manohar S, Kompotiatis P, Thongprayoon C, Cheungpasitporn W, Herrmann J, Herrmann SM (2018) Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant 34(1):108\u2013117. https:\/\/doi.org\/10.1093\/ndt\/gfy105","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"4260_CR79","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","volume":"20","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Rini BI, McDermott DF, Ar\u00e9n Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barth\u00e9l\u00e9my P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm M-O, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Gr\u00fcnwald V, McHenry MB, Mekan S, Tannir NM (2019) Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 20(10):1370\u20131385. https:\/\/doi.org\/10.1016\/S1470-2045(19)30413-9","journal-title":"Lancet Oncol"},{"issue":"3","key":"4260_CR80","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, Cornell LD, Feldman P, Stokes MB, Zapata SA, Hodi FS, Ott PA, Yamashita M, Leaf DE (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90(3):638\u2013647. https:\/\/doi.org\/10.1016\/j.kint.2016.04.008","journal-title":"Kidney Int"},{"issue":"12","key":"4260_CR81","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1816047","journal-title":"N Engl J Med"},{"issue":"12","key":"4260_CR82","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack ER, Souli\u00e8res D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Yin L, Chen M, Molife LR, Atkins MB, Rini BI (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 21(12):1563\u20131573. https:\/\/doi.org\/10.1016\/S1470-2045(20)30436-8","journal-title":"Lancet Oncol"},{"issue":"1","key":"4260_CR83","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s40425-018-0420-0","volume":"6","author":"A Amin","year":"2018","unstructured":"Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ (2018) Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer 6(1):109. https:\/\/doi.org\/10.1186\/s40425-018-0420-0","journal-title":"J Immunother Cancer"},{"issue":"3","key":"4260_CR84","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.ekir.2020.02.028","volume":"5","author":"WK Lo","year":"2020","unstructured":"Lo WK, Yau T, Chang TYA, Chan KW (2020) SAT-024 Glomerulonephritis induced by combination immunotherapy and VEGF inhibition with tyrosine kinase inhibitors (TKI). Kidney Int Rep 5(3):S12. https:\/\/doi.org\/10.1016\/j.ekir.2020.02.028","journal-title":"Kidney Int Rep"},{"issue":"1","key":"4260_CR85","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","volume":"97","author":"MA Perazella","year":"2020","unstructured":"Perazella MA, Shirali AC (2020) Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int 97(1):62\u201374. https:\/\/doi.org\/10.1016\/j.kint.2019.07.022","journal-title":"Kidney Int"},{"issue":"2","key":"4260_CR86","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/asn.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB, Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL, Sise ME, Leaf DE (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 31(2):435\u2013446. https:\/\/doi.org\/10.1681\/asn.2019070676","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4260_CR87","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","volume":"7","author":"O Mamlouk","year":"2019","unstructured":"Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A (2019) Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 7(1):2\u20132. https:\/\/doi.org\/10.1186\/s40425-018-0478-8","journal-title":"J Immunother Cancer"},{"issue":"4","key":"4260_CR88","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1053\/j.ajkd.2019.03.433","volume":"74","author":"R Shingarev","year":"2019","unstructured":"Shingarev R, Glezerman IG (2019) Kidney complications of immune checkpoint inhibitors: a review. Am J Kidney Dis 74(4):529\u2013537. https:\/\/doi.org\/10.1053\/j.ajkd.2019.03.433","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"4260_CR89","doi-asserted-by":"publisher","first-page":"130","DOI":"10.34067\/kid.0000852019","volume":"1","author":"S Gupta","year":"2020","unstructured":"Gupta S, Cortazar FB, Riella LV, Leaf DE (2020) Immune checkpoint inhibitor nephrotoxicity: update 2020. Kidney 360 1(2):130\u2013140. https:\/\/doi.org\/10.34067\/kid.0000852019","journal-title":"Kidney 360"},{"issue":"2","key":"4260_CR90","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, Launay-Vacher V, Jhaveri KD (2017) Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 45(2):160\u2013169. https:\/\/doi.org\/10.1159\/000455014","journal-title":"Am J Nephrol"},{"issue":"2","key":"4260_CR91","doi-asserted-by":"publisher","first-page":"e000213","DOI":"10.1136\/esmoopen-2017-000213","volume":"2","author":"C Granier","year":"2017","unstructured":"Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, Saldmann A, Gey A, Oudard S, Tartour E (2017) Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open 2(2):e000213. https:\/\/doi.org\/10.1136\/esmoopen-2017-000213","journal-title":"ESMO Open"},{"issue":"5","key":"4260_CR92","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5):541\u2013547. https:\/\/doi.org\/10.1016\/1074-7613(95)90125-6","journal-title":"Immunity"},{"issue":"2","key":"4260_CR93","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141\u2013151. https:\/\/doi.org\/10.1016\/s1074-7613(00)80089-8","journal-title":"Immunity"},{"issue":"8","key":"4260_CR94","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","volume":"5","author":"SM Herrmann","year":"2020","unstructured":"Herrmann SM, Perazella MA (2020) Immune checkpoint inhibitors and immune-related adverse renal events. Kidney Int Rep 5(8):1139\u20131148. https:\/\/doi.org\/10.1016\/j.ekir.2020.04.018","journal-title":"Kidney Int Rep"},{"issue":"7","key":"4260_CR95","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2215\/CJN.02340219","volume":"14","author":"MA Perazella","year":"2019","unstructured":"Perazella MA, Sprangers B (2019) AKI in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14(7):1077\u20131079. https:\/\/doi.org\/10.2215\/CJN.02340219","journal-title":"Clin J Am Soc Nephrol"},{"issue":"17","key":"4260_CR96","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/jco.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/jco.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"4260_CR97","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:119\u2013142. https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"issue":"1","key":"4260_CR98","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12882-018-0848-y","volume":"19","author":"R Koda","year":"2018","unstructured":"Koda R, Watanabe H, Tsuchida M, Iino N, Suzuki K, Hasegawa G, Imai N, Narita I (2018) Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report. BMC Nephrol 19(1):48. https:\/\/doi.org\/10.1186\/s12882-018-0848-y","journal-title":"BMC Nephrol"},{"issue":"1","key":"4260_CR99","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/psp4.12143","volume":"6","author":"G Bajaj","year":"2017","unstructured":"Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y (2017) Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacomet Syst Pharmacol 6(1):58\u201366. https:\/\/doi.org\/10.1002\/psp4.12143","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"10064","key":"4260_CR100","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Dur\u00e1n I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Th\u00e5str\u00f6m A, Abidoye OO, Fine GD, Bajorin DF (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389(10064):67\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(16)32455-2","journal-title":"Lancet"},{"issue":"4","key":"4260_CR101","doi-asserted-by":"publisher","first-page":"e772","DOI":"10.1016\/j.clgc.2019.04.004","volume":"17","author":"H Tachibana","year":"2019","unstructured":"Tachibana H, Kondo T, Ishihara H, Takagi T, Tanabe K (2019) Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma and end-stage renal disease at 2 centers. Clin Genitourin Cancer 17(4):e772\u2013e778. https:\/\/doi.org\/10.1016\/j.clgc.2019.04.004","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"4260_CR102","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.kint.2019.04.043","volume":"96","author":"A Capasso","year":"2019","unstructured":"Capasso A, Benigni A, Capitanio U, Danesh FR, Di Marzo V, Gesualdo L, Grandaliano G, Jaimes EA, Malyszko J, Perazella MA, Qian Q, Ronco P, Rosner MH, Trepiccione F, Viggiano D, Zoccali C, Capasso G, International Conference on Onco-Nephrology P (2019) Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney Int 96(3):555\u2013567. https:\/\/doi.org\/10.1016\/j.kint.2019.04.043","journal-title":"Kidney Int"},{"issue":"10246","key":"4260_CR103","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0140-6736(20)30540-7","volume":"396","author":"J Malyszko","year":"2020","unstructured":"Malyszko J, Tesarova P, Capasso G, Capasso A (2020) The link between kidney disease and cancer: complications and treatment. Lancet 396(10246):277\u2013287. https:\/\/doi.org\/10.1016\/S0140-6736(20)30540-7","journal-title":"Lancet"},{"issue":"12","key":"4260_CR104","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","volume":"30","author":"RJ Motzer","year":"2012","unstructured":"Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA (2012) Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30(12):1371\u20131377. https:\/\/doi.org\/10.1200\/JCO.2011.36.4133","journal-title":"J Clin Oncol"},{"issue":"21","key":"4260_CR105","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","volume":"295","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA J Am Med Assoc 295(21):2516\u20132524. https:\/\/doi.org\/10.1001\/jama.295.21.2516","journal-title":"JAMA J Am Med Assoc"},{"issue":"suppl","key":"4260_CR106","doi-asserted-by":"publisher","first-page":"abstr 4504","DOI":"10.1200\/jco.2013.31.15_suppl.4504","volume":"31","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Pittman KB, Sabbatini R, Rha SY, Flaig TW, Page RD, Bavbek SE, Beck JT, Patel PM, Schiff E, Vaury A, Niolat J, Gogov S, Anak O, Knox J (2013) Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 31(suppl):abstr 4504","journal-title":"J Clin Oncol"},{"issue":"3","key":"4260_CR107","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","volume":"28","author":"TE Hutson","year":"2010","unstructured":"Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA (2010) Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 28(3):475\u2013480. https:\/\/doi.org\/10.1200\/JCO.2008.21.6994","journal-title":"J Clin Oncol"},{"issue":"3","key":"4260_CR108","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.clgc.2013.04.006","volume":"11","author":"JD Hainsworth","year":"2013","unstructured":"Hainsworth JD, Rubin MS, Arrowsmith ER, Khatcheressian J, Crane EJ, Franco LA (2013) Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Clin Genitourin Cancer 11(3):270\u2013275. https:\/\/doi.org\/10.1016\/j.clgc.2013.04.006","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"4260_CR109","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061\u20131068. https:\/\/doi.org\/10.1200\/JCO.2009.23.9764","journal-title":"J Clin Oncol"},{"issue":"6","key":"4260_CR110","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","volume":"49","author":"CN Sternberg","year":"2013","unstructured":"Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID (2013) A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 49(6):1287\u20131296. https:\/\/doi.org\/10.1016\/j.ejca.2012.12.010","journal-title":"Eur J Cancer"},{"issue":"2","key":"4260_CR111","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, Group TS (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125\u2013134. https:\/\/doi.org\/10.1056\/NEJMoa060655","journal-title":"N Engl J Med"},{"issue":"20","key":"4260_CR112","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27(20):3312\u20133318. https:\/\/doi.org\/10.1200\/JCO.2008.19.5511","journal-title":"J Clin Oncol"},{"issue":"8","key":"4260_CR113","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","volume":"32","author":"TE Hutson","year":"2014","unstructured":"Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ (2014) Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32(8):760\u2013767. https:\/\/doi.org\/10.1200\/JCO.2013.50.3961","journal-title":"J Clin Oncol"},{"issue":"11","key":"4260_CR114","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","volume":"8","author":"O Rixe","year":"2007","unstructured":"Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8(11):975\u2013984. https:\/\/doi.org\/10.1016\/S1470-2045(07)70285-1","journal-title":"Lancet Oncol"},{"issue":"12","key":"4260_CR115","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/cas.12546","volume":"105","author":"M Eto","year":"2014","unstructured":"Eto M, Uemura H, Tomita Y, Kanayama H, Shinohara N, Kamei Y, Fujii Y, Umeyama Y, Ozono S, Naito S, Akaza H, Japan Axitinib Phase IISG (2014) Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma. Cancer Sci 105(12):1576\u20131583. https:\/\/doi.org\/10.1111\/cas.12546","journal-title":"Cancer Sci"},{"issue":"6","key":"4260_CR116","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","volume":"14","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI (2013) Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14(6):552\u2013562. https:\/\/doi.org\/10.1016\/S1470-2045(13)70093-7","journal-title":"Lancet Oncol"},{"key":"4260_CR117","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2147\/OTT.S83302","volume":"8","author":"S Qin","year":"2015","unstructured":"Qin S, Bi F, Jin J, Cheng Y, Guo J, Ren X, Huang Y, Tarazi J, Tang J, Chen C, Kim S, Ye D (2015) Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study. Onco Targets Ther 8:1363\u20131373. https:\/\/doi.org\/10.2147\/OTT.S83302","journal-title":"Onco Targets Ther"},{"issue":"1","key":"4260_CR118","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clgc.2016.05.008","volume":"15","author":"TE Hutson","year":"2017","unstructured":"Hutson TE, Al-Shukri S, Stus VP, Lipatov ON, Shparyk Y, Bair AH, Rosbrook B, Andrews GI, Vogelzang NJ (2017) axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase III trial. Clin Genitourin Cancer 15(1):72\u201376. https:\/\/doi.org\/10.1016\/j.clgc.2016.05.008","journal-title":"Clin Genitourin Cancer"},{"issue":"13","key":"4260_CR119","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","volume":"14","author":"TE Hutson","year":"2013","unstructured":"Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, Rosbrook B, Chen C, Kim S, Vogelzang NJ (2013) Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 14(13):1287\u20131294. https:\/\/doi.org\/10.1016\/S1470-2045(13)70465-0","journal-title":"Lancet Oncol"},{"issue":"11","key":"4260_CR120","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1634\/theoncologist.2019-0316","volume":"24","author":"DJ George","year":"2019","unstructured":"George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK (2019) Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the alliance A031203 CABOSUN trial. Oncologist 24(11):1497\u20131501. https:\/\/doi.org\/10.1634\/theoncologist.2019-0316","journal-title":"Oncologist"},{"issue":"6","key":"4260_CR121","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ (2017) Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol 35(6):591\u2013597. https:\/\/doi.org\/10.1200\/JCO.2016.70.7398","journal-title":"J Clin Oncol"},{"key":"4260_CR122","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","volume":"94","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ (2018) Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer 94:115\u2013125. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.012","journal-title":"Eur J Cancer"},{"issue":"7","key":"4260_CR123","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ, Investigators M (2016) Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17(7):917\u2013927. https:\/\/doi.org\/10.1016\/S1470-2045(16)30107-3","journal-title":"Lancet Oncol"},{"issue":"19","key":"4260_CR124","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Geczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, Investigators M (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1814\u20131823. https:\/\/doi.org\/10.1056\/NEJMoa1510016","journal-title":"N Engl J Med"},{"key":"4260_CR125","unstructured":"Pfizer Inc.. Sutent (sunitinib) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021938s037lbl.pdf. Revised Aug 2020. Accessed 20 Oct 2020"},{"key":"4260_CR126","unstructured":"Bayer HealthCare Pharmaceuticals Inc.. Nexavar (sorafenib) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021923s024lblrpl.pdf. Revised June 2020. Accessed 2020 Oct 2020"},{"key":"4260_CR127","unstructured":"Novartis Pharmaceuticals Corporation. Votrient (pazopanib) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022465s029lbl.pdf. Revised Aug 2020. Accessed 20 Oct 2020"},{"key":"4260_CR128","unstructured":"Pfizer Inc.. Inlyta (axitinib) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202324s011lbl.pdf. Revised June 2020. Accessed 20 Oct 2020"},{"key":"4260_CR129","unstructured":"Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022334s044,203985s016lbl.pdf. Revised Feb 2020. Accessed 20 Oct 2020"},{"key":"4260_CR130","unstructured":"Wyeth Pharmaceuticals Inc.. Torisel (temsirolimus) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022088s021s023lbl.pdf. Revised Mar 2018. Accessed 20 Oct 2020"},{"key":"4260_CR131","unstructured":"Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125377s115lbl.pdf. Revised Oct 2020. Accessed 20 Oct 2020"},{"key":"4260_CR132","unstructured":"Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125554s089lbl.pdf. Revised Oct 2020. Accessed 20 Oct 2020"},{"key":"4260_CR133","unstructured":"Merck Sharp & Dohme Corp.. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125514s085lbl.pdf. Revised Oct 2020. Accessed 20 Oct 2020"},{"key":"4260_CR134","unstructured":"Genentech Inc.. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761034s029lbl.pdf. Revised Sept 2020. Accessed 20 Oct 2020"},{"issue":"8","key":"4260_CR135","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/j.1464-410X.2010.09990.x","volume":"108","author":"D Josephs","year":"2011","unstructured":"Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF, Powles T, Chowdhury P, Karapetis C, Harper PG, Choueiri TK, Chowdhury S (2011) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 108(8):1279\u20131283. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09990.x","journal-title":"BJU Int"},{"issue":"15_suppl","key":"4260_CR136","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1200\/jco.2011.29.15_suppl.4646","volume":"29","author":"J Casper","year":"2011","unstructured":"Casper J, Goebel D, Gruenwald V, Fl\u00f6rcken A, Mueller D, Toussaint K, Metzner B (2011) Efficacy and safety of sunitinib in patients with metastatic renal cell carcinoma on hemodialysis. J Clin Oncol 29(15_suppl):4646\u20134646. https:\/\/doi.org\/10.1200\/jco.2011.29.15_suppl.4646","journal-title":"J Clin Oncol"},{"issue":"5","key":"4260_CR137","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1464-410X.2012.10946.x","volume":"110","author":"C Masini","year":"2012","unstructured":"Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, Buti S, Iacovelli R, Invernizzi R, Moscetti L, Aste MG, Pagano M, Grosso F, Lucia Manenti A, Ortega C, Cosmai L, Del Giovane C, Conte PF (2012) Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int 110(5):692\u2013698. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.10946.x","journal-title":"BJU Int"},{"issue":"5","key":"4260_CR138","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.clgc.2014.01.004","volume":"12","author":"AV Shetty","year":"2014","unstructured":"Shetty AV, Matrana MR, Atkinson BJ, Flaherty AL, Jonasch E, Tannir NM (2014) Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience. Clin Genitourin Cancer 12(5):348\u2013353. https:\/\/doi.org\/10.1016\/j.clgc.2014.01.004","journal-title":"Clin Genitourin Cancer"},{"issue":"16","key":"4260_CR139","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.2217\/fon.15.112","volume":"11","author":"AM Czarnecka","year":"2015","unstructured":"Czarnecka AM, Kawecki M, Lian F, Korniluk J, Szczylik C (2015) Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience. Future Oncol 11(16):2267\u20132282. https:\/\/doi.org\/10.2217\/fon.15.112","journal-title":"Future Oncol"},{"issue":"1","key":"4260_CR140","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s10147-015-0871-y","volume":"21","author":"K Omae","year":"2016","unstructured":"Omae K, Kondo T, Kennoki T, Takagi T, Iizuka J, Kobayashi H, Hashimoto Y, Tanabe K (2016) Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. Int J Clin Oncol 21(1):126\u2013132. https:\/\/doi.org\/10.1007\/s10147-015-0871-y","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"4260_CR141","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1471-2369-14-84","volume":"14","author":"J Syrios","year":"2013","unstructured":"Syrios J, Kechagias G, Tsavaris N (2013) Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review. BMC Nephrol 14(1):84. https:\/\/doi.org\/10.1186\/1471-2369-14-84","journal-title":"BMC Nephrol"},{"issue":"6","key":"4260_CR142","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1007\/s10147-012-0492-7","volume":"18","author":"H Miyake","year":"2013","unstructured":"Miyake H, Harada K, Kusuda Y, Fujisawa M (2013) Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis. Int J Clin Oncol 18(6):1054\u20131059. https:\/\/doi.org\/10.1007\/s10147-012-0492-7","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"4260_CR143","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/hdi.12390","volume":"20","author":"K Omae","year":"2016","unstructured":"Omae K, Kondo T, Takagi T, Iizuka J, Kobayashi H, Hashimoto Y, Tanabe K (2016) Use of mammalian target of rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: a single-center experience with four cases. Hemodial Int 20(3):E1-5. https:\/\/doi.org\/10.1111\/hdi.12390","journal-title":"Hemodial Int"},{"issue":"6","key":"4260_CR144","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.eururo.2016.05.040","volume":"70","author":"MI Carlo","year":"2016","unstructured":"Carlo MI, Feldman DR (2016) Response to nivolumab in a patient with metastatic clear cell renal cell carcinoma and end-stage renal disease on dialysis. Eur Urol 70(6):1082\u20131083. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.040","journal-title":"Eur Urol"},{"issue":"9","key":"4260_CR145","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/iju.13420","volume":"24","author":"T Tabei","year":"2017","unstructured":"Tabei T, Natsume I, Kobayashi K (2017) Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment. Int J Urol 24(9):708\u2013710. https:\/\/doi.org\/10.1111\/iju.13420","journal-title":"Int J Urol"},{"key":"4260_CR146","doi-asserted-by":"publisher","first-page":"1623957","DOI":"10.1155\/2018\/1623957","volume":"2018","author":"J Ansari","year":"2018","unstructured":"Ansari J, Ali M, Farrag A, Ali AM, Alhamad A (2018) Efficacy of nivolumab in a patient with metastatic renal cell carcinoma and end-stage renal disease on dialysis: case report and literature review. Case Rep Immunol 2018:1623957\u20131623957. https:\/\/doi.org\/10.1155\/2018\/1623957","journal-title":"Case Rep Immunol"},{"issue":"3","key":"4260_CR147","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10637-018-0673-y","volume":"37","author":"H Cheun","year":"2019","unstructured":"Cheun H, Kim M, Lee H, Oh KH, Keam B (2019) Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. Investig New Drugs 37(3):579\u2013583. https:\/\/doi.org\/10.1007\/s10637-018-0673-y","journal-title":"Investig New Drugs"},{"issue":"5","key":"4260_CR148","doi-asserted-by":"publisher","first-page":"e903","DOI":"10.1016\/j.clgc.2019.06.009","volume":"17","author":"MG Vitale","year":"2019","unstructured":"Vitale MG, Baldessari C, Milella M, Buti S, Militello AM, Di Girolamo S, Fornarini G, Perri G, Basso U, Maruzzo M, Porta C, Cosmai L, Pipitone S, Cerma K, Cascinu S, Sabbatini R (2019) Immunotherapy in dialysis-dependent cancer patients: our experience in patients with metastatic renal cell carcinoma and a review of the literature. Clin Genitourin Cancer 17(5):e903\u2013e908. https:\/\/doi.org\/10.1016\/j.clgc.2019.06.009","journal-title":"Clin Genitourin Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04260-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04260-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04260-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T06:07:56Z","timestamp":1620626876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04260-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":148,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["4260"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04260-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"13 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AB has received a travel grant from Novartis and honoraria from Janssen. PS has received travel grants from MSD, Roche, and Pierre Fabre. AMC has received travel grants and honoraria from BMS, MSD, Roche, and Novartis. \u0141M and ACJ declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}